Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065744 | 0.80 | CYP1A2 (0.43) | SRD5A2PTGDRPTGDR2CXCL8CHRM1 | |
| SCHEMBL883868 | 0.79 | ELANE (0.52) | ACHEVCAM1 | |
| SCHEMBL2066101 | 0.77 | PTGDR2 (0.45) | PTGDRPTGDR2 | |
| SCHEMBL883853 | 0.76 | PTGDR2 (0.49) | PTGDRPTGDR2 | |
| SCHEMBL883879 | 0.73 | PTGDR2 (0.42) | PTGDRPTGDR2 | |
| SCHEMBL6584544 | 0.73 | VCAM1 (0.57) | SRD5A2ACHEVCAM1 | |
| Water SCHEMBL27654072 | 0.72 | VCAM1 (0.55) | SRD5A2ACHEVCAM1 | |
| SCHEMBL13742003 | 0.70 | KDM4E (0.64) | PTGDRPTGDR2 | |
| SCHEMBL1415906 | 0.70 | SRD5A2 (0.73) | SRD5A2CAMK2A | |
| SCHEMBL6131922 | 0.70 | ACHE (0.71) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101326161-B | Novel compounds | ASTRAZENECA AB | 2013-04-17 | — | — | CN | claimed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-1937632-A1 | NOVEL COMPOUNDS | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| CN-101326161-B | Novel compounds | ASTRAZENECA AB | 2013-04-17 | — | — | CN | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1937632-A1 | NOVEL COMPOUNDS | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192163-A1 | Novel Compounds | PAH, PC, DDC | SRD5A2 1881/4885ACHE 2681/4885PTGDR 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.